TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29769054

Group type: EXPERIMENTAL
Intervention: Participation in organised social activities
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Attendance at religious activities
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Individual factors associated with social participation
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Barriers to social participation
Number of subjects: 1028
Study: 28269767

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 83

Group type: COMPARATOR
Intervention: Galantamine
Number of subjects: 83
Study: 25639148

Group type: EXPERIMENTAL
Intervention: Second-generation e-cigarettes
Number of subjects: 22

Group type: COMPARATOR
Intervention: First-generation e-cigarettes
Number of subjects: 22
Study: 23992601

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 21038765

Group type: EXPERIMENTAL
Intervention: All Stars Challenge intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 18219129

Group type: EXPERIMENTAL
Intervention: IVIg treatment guided by RT‐PCR
Number of subjects: 75

Group type: COMPARATOR
Intervention: IVIg treatment guided by viral isolation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RT‐PCR positive for enterovirus
Number of subjects: 75

Group type: COMPARATOR
Intervention: RT‐PCR negative for enterovirus
Number of subjects: 75
Study: 16797429

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study: 12022784

Group type: EXPERIMENTAL
Intervention: Early supported discharge (ESD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 82
Study: 10050217

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine with low bypass flow rate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine with high bypass flow rate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline with low bypass flow rate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline with high bypass flow rate
Number of subjects: 100
Study: 8526158

Group type: EXPERIMENTAL
Intervention: Autologous fatty tissue transplantation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nearby control crease (no intervention)
Number of subjects: 400
Study: 2317174

Group type: EXPERIMENTAL
Intervention: Sinusoidal vibration at 2.0 Hz
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sinusoidal vibration at 2.5 Hz
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Random vibration at 2.0 Hz
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Random vibration at 2.5 Hz
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Collimated display at frequencies above 1.6 Hz
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-collimated display at frequencies above 1.6 Hz
Number of subjects: 16
Study: 523424

Group type: EXPERIMENTAL
Intervention: Cholintheophyllinate (Euspirax) 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophyllin‐Aethylendiamine (Euphyllin retard) 350 mg
Number of subjects: 12
Study: 31559418

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 4859

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 4859
Study: 28711361

Group type: EXPERIMENTAL
Intervention: Elbow Flexed (EF) crutch setup
Number of subjects: 30

Group type: COMPARATOR
Intervention: Elbow Extended (EE) crutch setup
Number of subjects: 30
Study: 26975890

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) delivered via facial mask (inspiratory pressure support level, 5‐15 cm H2O; positive end‐expiratory pressure, 5‐10 cm H2O; fraction of inspired oxygen titrated to maintain SpO2 ≥94%) (n=148)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard oxygen therapy (up to 15 L/min to maintain SpO2 of 94% or higher) (n=145)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 293
Study: 24719249

Group type: EXPERIMENTAL
Intervention: Significant bacteriuria (6.5% of samples)
Number of subjects: 247
Study: 23964144

Group type: EXPERIMENTAL
Intervention: 90 mL of NaP (prep 1)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 45 mL of NaP + 20 mg of bisacodyl (prep 2)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 4 L of PEG (prep 3)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 2 L of PEG + 20 mg of bisacodyl (prep 4)
Number of subjects: 349

Group type: COMPARATOR
Intervention: NaP preparations (comparing all NaP preparations to PEG preparations)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Bisacodyl (in combination with NaP or PEG)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Whole dose NaP preparation (compared to half-dose PEG plus bisacodyl)
Number of subjects: 349
Study: 20466530

Group type: EXPERIMENTAL
Intervention: AZD4818 300 mug twice daily
Number of subjects: 65
Study: 18212717

Group type: EXPERIMENTAL
Intervention: Relaxing music for 15 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: No music (15-minute rest)
Number of subjects: 30
Study: 16489477

Group type: EXPERIMENTAL
Intervention: Continuous passive motion for 1 hour, twice a day, following total knee replacement surgery.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard rehabilitation protocol without continuous passive motion (Control group).
Number of subjects: 85
Study: 12860346

Group type: EXPERIMENTAL
Intervention: Vaccination against HPV16 E7 in SB adjuvant ASO2B
Number of subjects: 5

Group type: COMPARATOR
Intervention: Non-injected patients
Number of subjects: 5
Study: 10881949

Group type: EXPERIMENTAL
Intervention: Enteral nutrition and conventional intravenous fluids (n = 11)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional intravenous fluids only (n = 18)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (17 additional patients with major abdominal operations)
Number of subjects: 29
Study: 9433635

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8494127

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg, twice daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg, twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2963205

Group type: EXPERIMENTAL
Intervention: Percutaneous oestrogen therapy for 2 years, opposed by oral micronized progesterone (200 mg) during the second year
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐oestradiol valerate together with cyproterone acetate (CPA)
Number of subjects: 110
Study: 30431725

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) switched on
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-Level Laser Therapy (LLLT) switched off
Number of subjects: 44
Study: 26931110

Group type: EXPERIMENTAL
Intervention: Patient-controlled oral analgesia
Number of subjects: 77

Group type: COMPARATOR
Intervention: Parenteral analgesia
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study: 24967725

Group type: EXPERIMENTAL
Intervention: Shifting training (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (language and respiratory exercises, n=8)
Number of subjects: 17
Study: 22779286

Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride (APF) gel
Number of subjects: 12
Study: 20397811

Group type: EXPERIMENTAL
Intervention: NIPPV (Non-Invasive Positive Pressure Ventilation) restarted after 1 week of withdrawal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continued withdrawal from NIPPV for up to 6 months
Number of subjects: 10
Study: 18547537

Group type: EXPERIMENTAL
Intervention: Retinal implants (neural retinal progenitor cell layers with retinal pigment epithelium)
Number of subjects: 10
Study: 15821644

Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng x kg ‐1 x min ‐1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nitric oxide plus iloprost
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nitric oxide and nitric oxide plus iloprost
Number of subjects: 41
Study: 12399676

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vehicle cream (control group)
Number of subjects: 192
Study: 9678143

Group type: EXPERIMENTAL
Intervention: Prostaglandin gel with hygroscopic cervical dilators
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prostaglandin gel alone
Number of subjects: 40
Study: 8008103

Group type: EXPERIMENTAL
Intervention: Patient point-of-view (PPOV1) delivery of regularly ordered medication by a pharmacy technician to the nurse server once a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patient point-of-view (PPOV2) delivery of all medications (including stats and i.v.s) to the nurse server hourly between 0700 and 2300 hours
Number of subjects: 37

Group type: COMPARATOR
Intervention: Traditional medication cart
Number of subjects: 37
Study: 2686797

Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 51
Study: 1092283

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: All treatments (Chlorpromazine, Imipramine, Placebo)
Number of subjects: 714
Study: 6160280

Group type: COMPARATOR
Intervention: Trimecaine (2 mg/min IV after 80 mg jet-injection)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lidocaine (same schedule as trimecaine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no antiarrhythmic agents)
Number of subjects: 45
Study: 31763300

Group type: EXPERIMENTAL
Intervention: Topical mitomycin (0.4 mg/ml) applied for 5 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (control) applied for 5 min
Number of subjects: 80
Study: 28645428

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Primary cytoreductive surgery
Number of subjects: 201
Study: 25735310

Group type: EXPERIMENTAL
Intervention: Real-ABT (ankle balance taping with kinesiology tape)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No-ABT (control)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo-ABT (control)
Number of subjects: 9
Study: 23136121

Group type: EXPERIMENTAL
Intervention: Flavan-3-ol-enriched dark chocolate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: White chocolate
Number of subjects: 42
Study: 21160192

Group type: EXPERIMENTAL
Intervention: Sustained-release dinoprostone vaginal pessary followed 6 h later by high-dose oxytocin infusion
Number of subjects: 500

Group type: COMPARATOR
Intervention: Sustained-release dinoprostone vaginal pessary with concurrent high-dose oxytocin infusion
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sustained-release dinoprostone pessary followed 6 h later by high-dose oxytocin
Number of subjects: 500
Study: 19346225

Group type: EXPERIMENTAL
Intervention: Prior CABG patients
Number of subjects: 1026

Group type: COMPARATOR
Intervention: No prior CABG patients
Number of subjects: 1026
Study: 17724829

Group type: EXPERIMENTAL
Intervention: Combined therapy with prostamol Uno and tamsulosin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Monotherapy with prostamol Uno
Number of subjects: 58
Study: 14747429

Group type: EXPERIMENTAL
Intervention: Fluconazole (day 1: 400 mg; days 2-4: 200 mg) + Lumiracoxib (400 mg on day 4)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lumiracoxib (400 mg on day 4)
Number of subjects: 13
Study: 11391683

Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate (BBIC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study: 9521027

Group type: EXPERIMENTAL
Intervention: Compression therapy and treatment with HSE
Number of subjects: 293

Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 293
Study: 7994786

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 150
Study: 2683685

Group type: EXPERIMENTAL
Intervention: Self-instruction treatment using a modified version of the LOGO computer language (REFLECT) and videotape feedback
Number of subjects: 16

Group type: COMPARATOR
Intervention: LOGO problem-solving without self-instruction (Control)
Number of subjects: 16
Study: 1092765

Group type: EXPERIMENTAL
Intervention: Purified type 1 M protein vaccine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Buffer placebo
Number of subjects: 44
Study: 31634231

Group type: EXPERIMENTAL
Intervention: Hyperinflammatory subphenotype (39/104 ARDS patients)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Hyperinflammatory subphenotype (30/108 ARFA patients)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Persistent elevation of biomarkers of innate immunity
Number of subjects: 212

Group type: COMPARATOR
Intervention: Hypoinflammatory subphenotype
Number of subjects: 212
Study: 28578889

Group type: EXPERIMENTAL
Intervention: Telescopic-coated dental needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dental needle
Number of subjects: 60
Study: 26104503

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Comparison health and wellness intervention
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (decreased sports/exercise)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (maintained/increased sports/exercise)
Number of subjects: 171
Study: 24127444

Group type: EXPERIMENTAL
Intervention: Oral tetra-arsenic tetra-sulfide (RIF) 60 mg/kg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) 0.16 mg/kg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Oral tetra-arsenic tetra-sulfide (RIF) plus ATRA
Number of subjects: 242

Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) plus ATRA
Number of subjects: 242
Study: 21273347

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Capecitabine with bevacizumab
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Aspirin users
Number of subjects: 471

Group type: COMPARATOR
Intervention: Control group (Capecitabine monotherapy)
Number of subjects: 471
Study: 19584184

Group type: EXPERIMENTAL
Intervention: Levothyroxine administered in a fasting state
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Levothyroxine taken with breakfast
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Levothyroxine taken at bedtime
Number of subjects: 65
Study: 17215531

Group type: EXPERIMENTAL
Intervention: Single dose of nevirapine
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 15217581

Group type: EXPERIMENTAL
Intervention: 50 Gy IMRT (group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 66-70 Gy IMRT (group B)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acute skin toxicities
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acute mucositis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Late xerostomia at 3 months
Number of subjects: 23
Study: 12201825

Group type: EXPERIMENTAL
Intervention: Physiological dose (0.0017 mg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physiological dose (0.0033 mg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Supraphysiological dose (0.010 mg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Supraphysiological dose (0.025 mg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall increase in GH dose
Number of subjects: 13
Study: 9717787

Group type: COMPARATOR
Intervention: Heater probe
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation
Number of subjects: 41
Study: 7863248

Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine nocte (n = 86)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 2 x 150 mg/d nizatidine (n = 93)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 2 x 300 mg/d nizatidine (n = 90)
Number of subjects: 269

Group type: COMPARATOR
Intervention: nizatidine 150 mg nocte (116 patients)
Number of subjects: 269

Group type: COMPARATOR
Intervention: 2 x 150 mg nizatidine daily (121 patients)
Number of subjects: 269
Study: 2683542

Group type: EXPERIMENTAL
Intervention: Indomethacin, 0.8 mg/kg i.v. preoperatively followed by 100 mg rectally 8-hourly for 3 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 782497

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (400 mug daily)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Inhaled betamethasone valerate (800 mug daily)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (all types)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Higher dose of beclomethasone dipropionate
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Adrenal response to tetracosactrin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Adrenal function suppression
Number of subjects: 158
Study: 31469259

Group type: EXPERIMENTAL
Intervention: Lithium disilicate strengthened lithium aluminosilicate glass-ceramic (LAS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Conventional lithium-disilicate glass-ceramic (LDS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: New-generation polymer-based CAD/CAM resin composite (CS)
Number of subjects: 35
Study: 28088597

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) applied to the incision from postoperative days 1 through 4
Number of subjects: 265

Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD) applied to the incision from postoperative days 1 through 4
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD)
Number of subjects: 265
Study: 25465944

Group type: COMPARATOR
Intervention: Finasteride 5 mg alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Finasteride 5 mg with Tamsulosin 0.2 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg with Finasteride 5 mg
Number of subjects: 15
Study: 23368701

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and carboxymethylcellulose (HA/CMC) instillation after TURP
Number of subjects: 180

Group type: COMPARATOR
Intervention: Lubricant instillation after TURP (Control)
Number of subjects: 180
Study: 20421867

Group type: EXPERIMENTAL
Intervention: Valacyclovir (VACV) 1000 mg twice daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19060462

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream plus colchicine tablets (1-2 g/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Colchicine tablets (1-2 g/day)
Number of subjects: 76
Study: 17084566

Group type: COMPARATOR
Intervention: 25 g of soy protein (SP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 25 g of soy protein plus resistance exercise (SPE)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Placebo plus resistance exercise (PLE)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 25 g of maltodextrine (placebo) (PL)
Number of subjects: 46
Study: 14679365

Group type: EXPERIMENTAL
Intervention: Red Wine (RW) 500 ml/day (12% ethanol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 12% ETOH dilution 500 ml/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dealcoholized Red Wine (DRW) 500 ml/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Red Grape Juice (RGJ) 500 ml/day
Number of subjects: 24
Study: 11179106

Group type: EXPERIMENTAL
Intervention: NO2 (10-μg/m3 increment)
Number of subjects: 3912

Group type: EXPERIMENTAL
Intervention: TSP (10-μg/m3 increment)
Number of subjects: 3912

Group type: EXPERIMENTAL
Intervention: O3 (10-μg/m3 increment)
Number of subjects: 3912
Study: 9215818

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 100 mg/m2 orally on days 1 to 14, methotrexate 40 mg/m2 intravenously on days 1 and 8, fluorouracil 600 mg/m2 intravenously on days 1 and 8)
Number of subjects: 232

Group type: COMPARATOR
Intervention: LMF (chlorambucil 5 mg/m2 orally on days 1 to 14 with some I.V. cytostatic drugs)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 232

Group type: COMPARATOR
Intervention: LMF
Number of subjects: 232
Study: 8299603

Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 10
Study: 3106607

Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 324

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 324
Study: 29358444

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (HBEP) for 12 weeks, including step targets and resistance exercises.
Number of subjects: 20
Study: 26826622

Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stents (SES)
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Paclitaxel eluting stents (PES)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stents (SES) in insulin-treated patients
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Paclitaxel eluting stents (PES) in insulin-treated patients
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Angiographic follow-up presence
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Angiographic follow-up absence
Number of subjects: 1724
Study: 23451852

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment applied twice daily for 2 months
Number of subjects: 30
Study: 23290165

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (first tablet taken within 24 hours post-operation, administered daily for 14 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no anticoagulant postoperatively)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100